- Home
- SEVN vs HURA Comparison
SEVN vs HURA Comparison
Compare SEVN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEVN | HURA |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.2M | 131.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SEVN | HURA |
|---|---|---|
| Price | $9.13 | $0.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $12.13 | $10.00 |
| AVG Volume (30 Days) | 113.2K | ★ 306.4K |
| Earning Date | 02-18-2026 | 02-14-2026 |
| Dividend Yield | ★ 12.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $29,408,000.00 | N/A |
| Revenue This Year | $0.59 | N/A |
| Revenue Next Year | $14.72 | N/A |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.30 | $0.66 |
| 52 Week High | $13.97 | $5.27 |
Technical Indicators
Market Signals| Indicator | SEVN | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 27.79 |
| Support Level | $8.83 | $0.68 |
| Resistance Level | $9.30 | $0.73 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 79.55 | 9.03 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.